Every Form 4 that Septerna, Inc. (SEPN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SEPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SEPN filings page.
Septerna, Inc. (SEPN) reported that Chief Medical Officer Rajiv Patni received a grant of stock options for 275,000 shares of common stock on September 8, 2026, at an exercise price of $37.37 per share, expiring on September 7, 2036. According to the vesting terms, 25% of the underlying shares vest on August 24, 2027 and the remaining 75% vest in thirty-six substantially equal monthly installments thereafter, subject to his continuous service, resulting in reported holdings of 275,000 options after this grant.
Septerna, Inc. insider Daniel D. Long, who serves as SVP, Drug Discovery, reported an option exercise and same‑day sale of common stock. On September 1, 2026, he exercised options to acquire 3,333 shares of common stock at an exercise price of $2.76 per share and sold 3,333 shares of common stock at a weighted average price of $37.8271 per share in multiple trades between $37.34 and $38.21.
The sale was effected pursuant to a Rule 10b5-1 sales plan adopted on March 20, 2026, indicating the transactions were pre‑planned. Following the option exercise, Long held 9,085 options on Septerna common stock with a $2.76 exercise price, expiring on March 19, 2034, which vest in substantially equal monthly installments from March 1, 2024, subject to his continued service.
Third Rock Ventures V, L.P. reported acquisition or exercise transactions in a Form 4 filing for SEPN. The filing lists transactions totaling 147,200 shares at a weighted average price of $50.27 per share from August 12, 2026 to August 12, 2026.
RA Capital–affiliated entities reported open-market sales of Septerna, Inc. common stock. On 2026-08-12, RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P. each sold 746,500 shares of Septerna common stock at $42.50 per share, for total reported sales of 1,493,000 shares. The positions are reported as indirectly owned, with RA Capital Management, L.P., its general partner, and principals Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their respective pecuniary interests.
Septerna, Inc. President and COO Elizabeth Bhatt exercised stock options for a total of 25,000 shares of Common Stock on August 11, 2026, including 18,681 shares at an exercise price of $6.81 and 6,319 shares at $2.76. On the same date, she sold 25,000 Common Stock shares at $44.00 per share. The sale was effected pursuant to a Rule 10b5-1 sales plan adopted on October 20, 2025, and certain options vest in monthly installments subject to her continued service.
Septerna, Inc. reported that Daniel D. Long, SVP, Drug Discovery, exercised employee stock options covering 3,334 shares of common stock at an exercise price of $2.7600 per share on August 3, 2026, converting derivative awards into common shares.
On the same date he sold 3,334 shares of common stock in two blocks: 1,000 shares at a weighted average price of $33.9756 per share within a $33.39–$34.32 range, and 2,334 shares at a weighted average price of $34.6805 per share within a $34.43–$35.04 range. These sales were effected pursuant to a Rule 10b5-1 sales plan adopted on March 20, 2026. Related options vest in 48 equal monthly installments starting August 1, 2023 and March 1, 2024, subject to continued service.
Septerna, Inc. President and COO Elizabeth Bhatt reported transactions in company equity on July 15, 2026. She exercised stock options to acquire 4,000 shares of common stock at $6.81 per share and, pursuant to a Rule 10b5-1 sales plan adopted on October 20, 2025, completed a sale transaction of 4,000 shares of common stock at a weighted average price of $33.9935 per share, with individual sale prices ranging from $33.49 to $34.24. Following these transactions, she directly held 174,209 shares of common stock and 80,911 stock options (right to buy) with an exercise price of $6.81 per share, expiring on September 22, 2034.
Septerna, Inc. senior vice president of drug discovery Daniel D. Long reported an exercise-and-sell transaction in company stock. On July 1, 2026, he exercised stock options to acquire 3,333 shares of common stock at $2.76 per share and sold 3,333 shares in open-market transactions.
The sales occurred at weighted average prices of $34.0964 and $34.8141, with actual sale prices ranging from $33.49 to $35.10. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by Long.
Septerna, Inc. reported a Form 4 transaction showing a grant of stock options covering 15,000 shares of Common Stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036.
The options were granted to Dr. Simson and vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual stockholder meeting, subject to continued service. Under Dr. Simson’s arrangement with RA Capital Management, the option is held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP, and any net cash or stock from exercise will offset advisory fees owed to RA Capital’s adviser entities. The reporting persons disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest.
Septerna, Inc.’s Chief People Officer Samira Shaikhly reported a combined option exercise and share sale. She exercised stock options to acquire 2,178 shares of Common Stock at $6.81 per share, then sold 2,178 shares at $35.18 per share in an open-market transaction.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025. Following these transactions, she holds 793 Common Stock shares and 20,865 stock options directly.
Septerna, Inc. director Abraham Bassan reported receiving a grant of stock options as part of his compensation. He was awarded options covering 15,000 shares of common stock at an exercise price of $37.34 per share, expiring on June 25, 2036.
These options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders, as long as he continues serving the company through that vesting date. After this grant, his reported derivative holdings in this filing consist of these 15,000 options.
Septerna, Inc. director Shalini Sharp received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. They vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, subject to her continued service. Following this compensation grant, she holds 15,000 derivative securities directly.
Septerna, Inc. director Bernard Coulie received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. All 15,000 options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual stockholders’ meeting, as long as he continues serving the company through that date. This is a compensation-related award, not an open-market share purchase or sale.
Septerna, Inc. director Jeffrey K. Tong received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. Following this grant, Tong holds stock options on 15,000 shares directly.
According to the terms, the 15,000 option shares vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual stockholder meeting, provided Tong continues serving the company through the vesting date.
Septerna, Inc. director Keith Michael Gottesdiener received a grant of stock options covering 11,260 shares of common stock. The options carry an exercise price of $37.34 per share and expire on June 25, 2036.
These options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders, as long as he continues serving the company through that date. After this grant, he holds 11,260 stock options directly.
Septerna, Inc. director Alan Ezekowitz received a grant of stock options as part of his compensation. The award covers 15,000 options to acquire Septerna common stock at an exercise price of $37.34 per share, with the option term running until June 25, 2036.
These options vest in full on the earlier of June 26, 2027 or the date of Septerna’s next annual meeting of stockholders, provided he continues to serve the company through the vesting date. Following this grant, his directly held option position from this award totals 15,000 shares underlying common stock.
Septerna, Inc. reported that director Jake Simson received a grant of stock options covering 15,000 shares of common stock at an exercise price of $37.34 per share. The options vest in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided he continues to serve until that date.
Under an arrangement with RA Capital Management, L.P., Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. Any net cash or stock from exercising the option must be turned over to the adviser to offset advisory fees, and Simson disclaims beneficial ownership of the option and underlying shares.
Septerna, Inc. SVP of Drug Discovery Daniel D. Long reported option exercises and share sales in SEPN stock. On June 22, 2026, he exercised options for 4,471 shares at $11.70 per share and 10,529 shares at $2.76 per share, converting them into common stock.
On the same date, he sold 7,000 shares at a weighted average price of $35.9687 and 8,000 shares at $35.1001 in open-market transactions under a pre-arranged Rule 10b5-1 sales plan. After these transactions, he directly holds 96,412 shares of common stock.
Septerna, Inc. Chief People Officer Samira Shaikhly reported an exercise-and-sale transaction in company stock. On June 12, 2026, she exercised options to acquire 6,250 shares of common stock at $11.70 per share, then sold 6,250 shares in an open-market transaction at a weighted average price of $35.0759 per share, with individual sale prices ranging from $35.00 to $35.19. These trades were executed under a pre-arranged Rule 10b5-1 sales plan. Following the transactions, she directly holds 793 shares of common stock and 23,750 stock options that remain outstanding and are scheduled to expire on August 6, 2035, continuing to give her equity exposure to Septerna’s future performance.
Septerna, Inc.’s Chief People Officer Samira Shaikhly reported an exercise-and-sell sequence in company stock. She exercised options to acquire 5,935 shares of common stock at exercise prices of $1.55 and $2.76 per share, then sold 5,935 shares in open-market transactions at weighted average prices of $27.78, $28.79 and $29.66 per share, within ranges from $27.24 to $30.08. The sales were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025.
Septerna, Inc. Chief People Officer Samira Shaikhly reported an option exercise and related share sale. She exercised stock options to acquire 11,798 shares of common stock at an exercise price of $6.81 per share, then sold 11,798 shares in open-market transactions at a weighted average price of $30.0607 per share.
The sales were made under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025, and executed in multiple trades between $30.00 and $30.24 per share. After these transactions, she directly owned 793 shares of Septerna common stock.
Septerna, Inc. President and COO Elizabeth Bhatt exercised stock options and sold shares in a planned transaction. She exercised options for 4,000 shares of Common Stock at an exercise price of $6.81 per share, then sold the same 4,000 shares in open-market trades at weighted average prices between about $23.33 and $25.91. The sales were made under a pre-arranged Rule 10b5-1 sales plan adopted on October 20, 2025. Following these transactions, she directly owned 174,535 shares of Common Stock.
Septerna, Inc. Chief People Officer Samira Shaikhly exercised several stock options on March 2, 2026, converting 53,714, 11,638, and 5,101 option shares into common stock at exercise prices of $1.55 and $2.76 per share. She then sold a total of 70,453 common shares in open-market transactions at weighted-average prices of $27.5052 and $28.1383, under a pre-arranged Rule 10b5-1 sales plan adopted on October 31, 2025. After these trades, she directly held 793 Septerna common shares, a balance that includes shares acquired through the company’s 2024 Employee Stock Purchase Plan.
Septerna, Inc. President and COO Elizabeth Bhatt reported option exercises and stock sales. On February 18, 2026, she exercised stock options for 4,000 shares at an exercise price of $6.81 per share and received 4,000 shares of common stock.
She then sold 2,200 shares of common stock at a weighted average price of $28.4594 per share and 1,800 shares at a weighted average price of $29.5831 per share in open‑market transactions under a Rule 10b5‑1 sales plan adopted on October 20, 2025. After these trades, she directly owned 174,209 shares of common stock and held 88,911 stock options.
Septerna, Inc. reported an insider equity award for Daniel D. Long, its SVP of Drug Discovery. On February 6, 2026, he was granted a stock option to buy 80,000 shares of common stock at an exercise price of $25.41 per share.
According to the vesting schedule, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as he continues to provide service to Septerna.
Septerna, Inc. officer Uwe Klein, SVP, Biological Sciences, received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $25.41 per share and were awarded on February 6, 2026.
According to the vesting schedule, 2/48 of the option shares will vest and become exercisable on March 1, 2026, with the remaining shares vesting in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Klein’s continued service with Septerna.
Septerna, Inc. reported that Chief People Officer Samira Shaikhly received a new stock option grant. On February 6, 2026, she was awarded options to purchase 80,000 shares of Septerna common stock at an exercise price of $25.41 per share, held as direct ownership.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining portion will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on her continued service. The option is scheduled to expire on February 5, 2036.
Septerna, Inc.'s Chief Financial Officer, Gil M. Labrucherie, received a grant of stock options on 125,000 shares of common stock on February 6, 2026, with an exercise price of $25.41 per share and direct ownership.
According to the vesting terms, 2/48 of the option vests and becomes exercisable on March 1, 2026. The remaining shares vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as the executive remains in continuous service with Septerna. The options expire on February 5, 2036.
Septerna’s Chief Medical Officer, Kim Jae B., reported receiving a new stock option award in common stock. On February 6, 2026, a stock option covering 125,000 shares was granted with an exercise price of $25.41 per share.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Kim’s continuous service with Septerna. After this grant, Kim holds 125,000 stock options directly.
Septerna, Inc. reported that President and COO Elizabeth Bhatt received a stock option grant on February 6, 2026. The option covers 155,000 shares of common stock at an exercise price of $25.41 per share and is held directly.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as Bhatt continues to provide service to Septerna.
Septerna, Inc. reported a stock option grant to its Chief Executive Officer and director, Jeffrey Finer. On February 6, 2026, he was awarded a stock option to purchase 400,000 shares of Septerna common stock at an exercise price of $25.41 per share.
The option expires on February 5, 2036. According to the vesting schedule, 2/48 of the shares will vest and become exercisable on March 1, 2026, and the remaining shares will vest in 46 substantially equal monthly installments, subject to his continuous service with the company.
Septerna, Inc. reported that its Chief Legal Officer, Mark Andrew Wilson, received a grant of stock options on February 6, 2026. The grant covers 165,000 stock options, each allowing the purchase of one share of Septerna common stock at an exercise price of $25.41 per share.
According to the vesting terms, 25% of the shares underlying the option will vest on January 5, 2027, with the remaining 75% vesting in thirty-six substantially equal monthly installments after that date, contingent on his continued service with the company.
Septerna, Inc. (SEPN) Form 4: An executive identified as SVP, Drug Discovery reported a sale of 3,501 shares of common stock on 11/10/2025, coded “S.” The weighted average sale price was $18.0586.
The filing notes sales occurred across a price range of $18.04 to $18.16. Following the transaction, the reporting person beneficially owns 92,911 shares, held directly.
According to the footnote, this figure includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on 10/31/2025 in transactions exempt under Rule 16b-3(c).
Septerna, Inc. director Keith Michael Gottesdiener was granted a stock option to purchase 33,246 shares of common stock with an exercise price of $16.75. The option was issued on 09/25/2025, becomes exercisable in monthly installments equal to 1/36th of the shares beginning on that date (subject to continued service), and expires on 09/24/2035. Following the reported transaction, the reporting person beneficially owned 33,246 option shares, held directly. The Form 4 was signed via attorney-in-fact on 09/29/2025. No other securities or cash transactions are reported.